Liver Organotropism and Biotransformation of a Novel Platinum-Ursodeoxycholate Derivative, Bamet-UD2, with Enhanced Antitumour Activity

References

• Anderson H., Wagstaff J., Crowther D., Swindell R., Lind M. J., McGregor J., Timm M. S., Brown D., Palmer P. Comparative toxicity of cisplatin, carboplatin (CBDCA) and iproplatin (CHIP) in combination with cyclophosphamide in patients with advanced epithelial ovarian cancer. Eur. J. Cancer Clin. Oncol 1988; 24: 1471–1479
   PubMedGoogle Scholar
• Berry M. N., Friend D. S. High-yield preparation of isolated rat liver parenchymal cells. J. Cell Biol 1969; 43: 506–520
   PubMed Web of Science ®Google Scholar
• Bradner W. T., Rose W. C., Huttalen J. B. Antitumor activity of platinum analogs. Cisplatin: Current Status and New Developments, A. W. Prestayko, S. T. Crooke, S. K. Carter. Academis Press, New York 1980; 171–182
   Google Scholar
• Carlsson G., Gullberg B., Hafstrom L. Estimation of liver tumor volume using different formulas – An experimental study in rats. J. Cancer Res. Clin. Oncol 1983; 105: 20–23
   PubMed Web of Science ®Google Scholar
• Criado J. J., Herrera M. C., Palomero M. F., Medarde M., Rodriguez E., Marin J. J.G. Synthesis and characterization of a new bile acid and platinum(II) complex with cytostatic activity. J. Lipid. Res 1997a; 38: 1022–1032
   PubMed Web of Science ®Google Scholar
• Criado J. J., Macias R. I.R., Medarde M., Monte M. J., Serrano M. A., Marin J. J.G. Synthesis and characterization of a new cytostatic complex cis-diammineplatinum(II) chlorocholylglycinate. Bioconjugate Chem 1997b; 8: 453–458
   PubMed Web of Science ®Google Scholar
• Criado J. J., Dominguez M. F., Medarde M., Fernandez E. R., Macias R. I.R., Marin J. J.G. New cis-diamminebis-cholylglycinate(O,O') Pt(II) and cis-diamminebisursodeoxycholate(O,O') Pt(II) complexes Structural characterization, kinetic studies and biological activity. Bioconjugate Chem 2000; 11: 167–174
   PubMed Web of Science ®Google Scholar
• Fautz R., Husein B., Efstahiou E., Hechenberger-Freundl C. Assessment of the relation between the initial viability and the attachement of freshly isolated hepatocytes used for the in vivo/in vitro DNA assay (USD). Mutation Res 1993; 291: 21–27
   PubMed Web of Science ®Google Scholar
• Hofmann A. F. Biliary secretion and excretion -The hepatobiliary component of the enterohepatic circulation of bile acids. Physiology of the Gastrointestinal Tract, L. R. Jonhson. Raven Press, New York 1994; 1555–1576
   Google Scholar
• Ho N. F.H. Utilizing bile-acid carrier mechanisms to enhance liver and intestine absorption. Ann. N. Y. Acad. Sci 1987; 907: 315–329
   Web of Science ®Google Scholar
• Klaassen C. D. Bile flow and composition during bile acid depletion and administration. Can. J. Physiol. Pharmacol 1974; 52: 334–348
   PubMed Web of Science ®Google Scholar
• Kramer W., Wess G., Schubert G., Bickel R., Girbig F., Gutjahr U., Neckermann G., Schulx S., Petzinger E. Liver-specific drug targeting by coupling to bile acids. J. Biol. Chem 1992; 267: 18598–18604
   PubMed Web of Science ®Google Scholar
• Larena M. G., Martinez-Diez M. C., Dominguez M. F., Macias R. I.R., Serrano M. A., Marin J. J.G. In vitro antiproliferative effect of two new platinum-containing bile acid derivates: Bamet-U2 and Bamet-D3. Anticancer Res 1998; 18: 4906, ‘Abstract’
   Google Scholar
• Liang D., Hagenbuch B., Stieger B., Meier P. J. Parallel decrease of Na+-taurocholatecotransport and its encoding messenger RNA in primary cultures of rat hepatocytes. Hepatology 1993; 18: 1162–1166
   PubMed Web of Science ®Google Scholar
• Lipp H. P., Bokemeyer C. Clinical pharmacokinetics of cytostatic drugs: efficacy and toxicity. Anticancer Drug Toxicity. Prevention, Management and Clinical Pharmacokinetics, H-P. Lipp, Tübingen 1999; 61–81
   Google Scholar
• Loeher P. J., Einhorn L. H. Cisplatin. Ann. Intern. Med 1984; 100: 704–713
   PubMed Web of Science ®Google Scholar
• Macias R. I.R., Monte M. J., El-Mir M. Y., Villanueva G. R., Marin J. J.G. Transport and biotransformation of the new cytostatic complex cis-diammineplatinum (II)-chlorocholylclycinate (Bamet-R2) by the rat liver. J. Lipid Res 1998; 39: 1792–1798
   PubMed Web of Science ®Google Scholar
• Macias R. I.R., El-Mir M. Y.A., Monte M. J., Serrano M. A., Garcia M. J., Marin J. J.G. Cholephilic characteristics of a new cytostatic complex of cisplatin with glycocholate (Bamet-R2). J. Controlled Release 1999; 57: 161–169
   PubMed Web of Science ®Google Scholar
• Marin J. J.G., Macias R. I.R., Criado J. J., Bueno A., Monte M. J., Serrano M. A. DNA interaction and cytostatic activity of the new liver organotropic complex of cisplatin with glycocholic acid: Bamet-R2. Int. J. Cancer 1998a; 78: 346–352
   PubMed Web of Science ®Google Scholar
• Marin J. J.G., Herrera M. C., Palomero M. F., Macias R. I.R., Monte M. J., El-Mir M. Y.A., Villanueva G. R. Rat liver transport and biotransformation of a cytostatic complex of bischolylglycinate and platinum(II). J. Hepatol 1998b; 28: 417–425
   PubMed Web of Science ®Google Scholar
• Marin J. J.G., Palomero M. F., Herrera M. C., Macias R. I.R., Criado J. J., Serrano M. A. In vitro cytostatic activity and DNA-interaction of the new liver organotropic complex chloro-bis-ckolylglycinate-platinum (II). Anticancer Res 1998c; 18: 1641–1648
   PubMed Web of Science ®Google Scholar
• Markwell M. A.K., Haas S. M., Beiber L. L., Tolbert N. E. A modification of the Lowry procedure to simplify protein determination in membrane and lipoprotein samples. Anal. Biochem 1978; 87: 206–210
   PubMed Web of Science ®Google Scholar
• Marshall N. J., Goodwin C. J., Holt S. J. A critical assessment of the use of microculture tetrazolium assays to measure cell growth and function. Mini review Growth Regul 1995; 5: 69–84
   PubMedGoogle Scholar
• Monte M. J., Dominguez S., Palomero M. F., Macias R. I.R., Marin J. J.G. Further evidence of the usefulness of bile acids as molecules for shuttling cytostatic drugs toward liver tumors. J. Hepatol 1999; 31: 521–528
   PubMed Web of Science ®Google Scholar
• Palomero M. F., Herrera M. C., Macias R. I.R., El-Mir M. Y.A., Villanueva G. R., Marin J. J.G. Transient enterohepatic circulation and enhanced biliary versus urinary excretion of the cytostatic drug bischolylglycinate-chloroplatinum(II) (Bamet-H2). Int. J. Pharmaceutics 1998; 172: 79–88
   Web of Science ®Google Scholar
• Stephan Z. F., Yurachek E. C., Sharif R., Wasvary J. M., Steele R. E., Howes C. Reduction of cardiovascular and thyroxine-suppressing activities of L-T2 by liver targeting with cholic acid. Biochem. Pharmacol 1992; 43: 1969–1974
   PubMed Web of Science ®Google Scholar
• Trauner M., Graziadei I. W. Review article: mechanisms of action and therapeutic applications of ursodeoxycholic acid in chronic liver diseases. Alimentary Pharmacol, and Therapeutics 1999; 13: 979–995
   PubMed Web of Science ®Google Scholar
• Villanueva G. R., Mendoza M. E., El-Mir M. Y.A., Monte M. J., Herrera M. C., Marin J. J.G. Effect of bile acids on hepatobiliary transport of cisplatin by perfused rat liver. Pharmacol. Toxicol 1997; 80: 111–117
   PubMedGoogle Scholar
• Yamaoka K., Nakagawa T., Uno T. Statistical moments in pharmacokinetics. J. Pharmacokinet. Biopharm 1978; 6: 547–557
   PubMedGoogle Scholar